Related references
Note: Only part of the references are listed.Personalized extended interval dosing of natalizumab in MS A prospective multicenter trial
Zoe L. E. van Kempen et al.
NEUROLOGY (2020)
Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing
John F. Foley et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
Zoe L. E. van Kempen et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
Zoe L. E. van Kempen et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
Efficacy and safety of natalizumab extended interval dosing
Bassem Yamout et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Recognition of viral and self-antigens by TH1 and TH1/TH17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses
Moira Paroni et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis
Kumar Kandadi Muralidharan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
Pei-Ran Ho et al.
LANCET NEUROLOGY (2017)
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
Tatiana Plavina et al.
NEUROLOGY (2017)
New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies
T. Sehr et al.
JOURNAL OF NEUROINFLAMMATION (2016)
Extended interval dosing of natalizumab in multiple sclerosis
L. Zhovtis Ryerson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
CD4 cell response to interval therapy with natalizumab
Regina Berkovich et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study
Robert J. Fox et al.
NEUROLOGY (2014)
JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab
Elliot M. Frohman et al.
JAMA NEUROLOGY (2014)
Extended interval dosing of natalizumab: a two-center, 7-year experience
Roberto Bomprezzi et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)
JC Viremia in Natalizumab-Treated Patients with Multiple Sclerosis
Eugene O. Major et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Natalizumab Bench to Bedside and Beyond
Richard Rudick et al.
JAMA NEUROLOGY (2013)
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Gary Bloomgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody
Theo Rispens et al.
ANALYTICAL BIOCHEMISTRY (2011)
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
B. O. Khatri et al.
NEUROLOGY (2009)
Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
Maria del Pilar Martin et al.
ARCHIVES OF NEUROLOGY (2008)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
BK Kleinschmidt-DeMasters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
A Langer-Gould et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
